01947nas a2200313   4500000000100000008004100001260001000042653001300052653004600065653001600111653003900127653001700166100001400183700001000197700001300207700001500220700002400235700001600259700001400275700001500289700001400304700001200318700001200330245005500342856026000397300000800657520094300665022002501608       2024                            d  bWiley10aJapanese10amycobacterium ulcerans subsp. shinshuense10aMycolactone10aNeglected tropical diseases (NTDs)10aTransmission1 aFukaura R1 aAto M1 aMurase C1 aMiyamoto Y1 aSugawara‐Mikami M1 aTakahashi T1 aHoshino Y1 aFujimoto N1 aAkiyama M1 aIshii N1 aYotsu R00aBuruli ulcer: An epidemiological update from Japan  uhttps://scholar.google.com/scholar_url?url=https://onlinelibrary.wiley.com/doi/pdf/10.1111/1346-8138.17483&hl=en&sa=X&d=2571156870775394730&ei=4W0FZ-7wGMa06rQPtp7HyAg&scisig=AFWwaeYKPpb8WTUYLvrkuMl-VktR&oi=scholaralrt&hist=K3bRSt0AAAAJ:9259899638232372953  a1-83 a<p>Japan is one of the rare non‐tropical countries with documented cases of Buruli ulcer (BU). Mycobacterium ulcerans subsp. shinshuense has been identified as the causative agent. The first report of BU in Japan dates back to 1982, with sporadic reports thereafter. Recently, the number of cases has been on the increase, and 50 cases (57.7%) are from the past decade alone, out of a total of 87 cases reported to date. Japan's well‐developed healthcare facilities play a crucial role in enabling detailed investigations and providing appropriate treatment for patients, contributing to a favorable prognosis. However, the rarity of the disease results in lack of awareness among healthcare professionals, leading to frequent delays in diagnosis. This article aims to offer an updated overview of BU cases in Japan and to raise awareness of BU among dermatologists and other healthcare professionals in a non‐endemic setting.</p>
  a0385-2407, 1346-8138